Business Wire

OH-PARKER-AEROSPACE

24.4.2024 16:01:32 CEST | Business Wire | Press release

Share
Parker Aerospace Joins HyFIVE Consortium to Advance Aviation Liquid Hydrogen Fuel System Development

Parker Aerospace, a business segment of Parker Hannifin Corporation, the global leader in motion and control technologies, will participate in the HyFIVE consortium of industry and academic partners developing a world-leading liquid hydrogen fuel system and supply chain supporting zero-emission aviation in the 2030s.

In addition to Parker Aerospace, HyFIVE includes fellow industry partners Marshall and GKN Aerospace, as well as academic partners University of Manchester, University of Bath and Cardiff University. The project is supported by the ATI Programme, a partnership between the UK’s Department for Business and Trade, the Aerospace Technology Institute (ATI) and Innovate UK (UKRI). The consortium will receive initial funding of £17 million ($21.5 million) from industry, matched by £20 million ($25 million) from the UK Government.

A path to zero emissions flight

The objective of the HyFIVE consortium is to develop, test and validate a modular and scalable cryogenic hydrogen fuel system architecture appropriate for multiple types of aircraft, and support of hydrogen electric propulsion or hydrogen combustion powertrains. The initiative will address technology development for hydrogen fuel systems in five key areas: storage, conveyance, indication, fueling and venting.

Collaboration among industry leaders

Parker Aerospace, which includes Parker Meggitt, has a broad spectrum of solutions for both airframes and engines and will furnish its advanced technology and expertise in the areas of sensing, thermal management and fluid conveyance.

Marshall will be leading the HyFIVE efforts, providing its expertise in complex system design, integration and certification, honed over decades of delivering aircraft fuel systems and complex aircraft modification projects.

GKN Aerospace, specializing in the design, manufacture and assembly of aircraft structures, engine components and systems, will contribute its industry-leading advanced materials and hydrogen cryogenic system optimization expertise.

Academic partners University of Manchester, University of Bath and Cardiff University have been selected for their world-leading research capabilities and advanced testing facilities in the areas of hydrogen-electric propulsion, cryogenic applications, power transmission, turbomachinery and next-generation material development.

Technical program detailed

The HyFIVE consortium members have defined a full technical program spanning several years, from initial architecture development and supplier engagement to ground testing and final design review for the integrated fuel system.

By 2027, the consortium plans to:

  • Develop and validate an integrated family of mature fuel system technologies and capabilities conducive to certification.
  • Conduct ground demonstration of an integrated fuel system encompassing the storage, conveyance, indication, venting and fueling systems.
  • Open a range of flight demonstration and exploitation paths with prospective customers.
  • Develop a customer-ready supply chain and industrialization strategy.

The timely achievement of these objectives will support the successful introduction of a new generation of zero-emissions aircraft in the 2030s.

"Parker is fully committed to sustainability, which is why we are making focused investments in innovative, next-generation technologies,” said Tracy Rice, vice president of technology and innovation for Parker Aerospace. “Hydrogen fuel systems play a critical role in achieving zero emissions in aviation and working with our partners on this project will enable us to further advance our expertise in this area and drive the development of innovative solutions that support a more sustainable future.”

About Parker Aerospace. At Parker Aerospace, we develop technologies and innovative solutions that enable reliable, efficient and increasingly sustainable flight for the lifecycle of the aircraft, including aftermarket support. Parker stands at the forefront of aviation technology with an expanded range of products and services that sits nose-to-tail across the entire aircraft. Our passionate people with deep engineering expertise, together with our breadth of differentiated technologies, ensure that we make the extraordinary happen and continue to shape the future of aviation in partnership with our customers.

About Parker Hannifin. Parker is a Fortune 250 global leader in motion and control technologies. For more than a century the company has been enabling engineering breakthroughs that lead to a better tomorrow. Learn more at www.parker.com or @parkerhannifin.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240424285169/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vertex to Present New Data on ALYFTREK® at the North American Cystic Fibrosis Conference9.10.2026 19:15:00 CEST | Press release

- Data on ALYFTREK in children ages 2 to 5 years demonstrate recovery of pancreatic function in some children –- Additional abstracts on clinical and real-world evidence on CFTR modulators also presented - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced new interim data from the ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor) 2 to 5 years old open-label extension study, highlighting recovery of exocrine pancreatic function in some children in that age group, allowing those children to discontinue pancreatic enzyme replacement therapy (PERT). Pancreatic exocrine insufficiency in children with cystic fibrosis (CF) was previously believed to be irreversible. These data were presented at the North American Cystic Fibrosis Conference (NACFC). “The data presented at NACFC underscore the safety and efficacy of our CF medicines in the real world and in clinical trials in younger age groups. The data from the Phase 3 open-label study in 2 to 5 year olds evaluating exocrine p

Andersen Consulting udvider med TalentSmartEQ for at fremme lederskab og virksomhedstransformation9.10.2026 18:48:00 CEST | Pressemeddelelse

Andersen Consulting styrker sine kompetencer inden for humankapital gennem en samarbejdsaftale med TalentSmartEQ, en San Diego-baseret virksomhed, der har fokus på at skabe praktiske, engagerende og handlingsorienterede læringsoplevelser med udgangspunkt i emotionel intelligens (EQ) og lederudvikling. I mere end to årtier har TalentSmartEQ arbejdet sammen med organisationer verden over med henblik på at udvikle ledelseskompetencer ved hjælp af emotionel intelligens og dermed styrke medarbejderengagement, teamwork og de samlede resultater. Virksomheden kombinerer forskningsbaserede metoder med praktiske læringsforløb, vurderinger, coaching og skræddersyede programmer, der skal omsætte opbygningen af emotionel intelligens til vedvarende ændringer i adfærden på arbejdspladsen. Som førende aktør i branchen samarbejder TalentSmartEQ med organisationer lige fra Fortune 500-virksomheder til offentlige myndigheder og privatejede virksomheder. "Organisationer stiller stadig større krav til dere

Verdant Rock Receives A (low) Financial Strength Rating from Morningstar DBRS, Adding a Second International Investment-Grade Assessment9.10.2026 16:00:00 CEST | Press release

Verdant Rock now holds Financial Strength Ratings from both Fitch Ratings and Morningstar DBRS, providing counterparties with dual-agency confirmation and reinforcing the security architecture behind each financial guarantee Verdant Rock Limited, a Bermuda Monetary Authority-regulated Class 3B insurance company, has received an A (low) Financial Strength Rating from Morningstar DBRS. The rating reflects Verdant Rock’s financial strength and its capacity to meet policyholder obligations as an investment-grade financial guarantor for Emerging Markets credit. Morningstar DBRS is a global credit rating agency with coverage across North America, Europe, Asia, and Latin America. Its assessment of Verdant Rock reflects the company’s strong projected earnings ability, robust risk profile, sound liquidity, and good capitalization. Morningstar DBRS also assigned an A (low) Issuer Rating to Verdant Rock. The rating follows Verdant Rock’s BBB+ Long-Term Insurer Financial Strength Rating with a Sta

Tecnotree Named a Visionary in the Inaugural 2026 Gartner® Magic Quadrant™ for CSP AI-Enabled Marketing and Sales Solutions9.10.2026 15:17:00 CEST | Press release

We think Gartner recognizes Tecnotree's open, governed approach to agentic AI as operators make AI the engine of their revenue operations Tecnotree, a global digital platform and services leader for AI, 5G, and cloud-native technologies, today announced that Gartner has positioned it as a Visionary in the first-ever Magic Quadrant for AI-Enabled CSP Marketing and Sales Solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261009905430/en/ Tecnotree Named a Visionary in the Inaugural 2026 Gartner® Magic Quadrant™ for CSP AI-Enabled Marketing and Sales Solutions A new category for a new operating model. CSPs are fighting saturated markets, rising acquisition costs, and accelerating churn. They are responding with AI-driven automation across the full revenue cycle, from segmentation and campaigns to lead management, CPQ, and renewals, increasingly executed by autonomous agents. According to us, Gartner creation of this Magi

Positive New Data on Corcym’s Perceval Plus Sutureless Aortic Heart Valve Encompasses up to 7-Year Follow-up9.10.2026 15:15:00 CEST | Press release

Data Presented at Annual Meeting of European Association for Cardio-Thoracic Surgery (EACTS), Along with 6 Perceval Plus E-PostersEACTS Also Marks Commercial Launch of TriMemo and Memo 4D Curve, Innovative Repair Devices for Tricuspid and Mitral Valves Corcym, a global medical device company dedicated to cardiac surgery, today announced that positive mid-term data from a sub-analysis of its Perceval Plus sutureless aortic heart valve as part of its MANTRA clinical trial was featured in an oral presentation today at the annual meeting of the European Association for Cardio-Thoracic Surgery (EACTS). The study is the longest follow-up available for Perceval Plus and the FREE tissue treatment from an international multicenter study, and demonstrated excellent durability, safety and quality of life improvements. Perceval Plus is the only sutureless and collapsible aortic surgical heart valve. Its unique design performs in any surgical scenario and is optimal for endoscopy and robotics. The

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye